Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deutetrabenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Registrational; Therapeutic Use
  • Acronyms AIM-TD
  • Sponsors Auspex Pharmaceuticals
  • Most Recent Events

    • 02 Oct 2019 According to a Teva Pharmaceutical Industries media release, data from analysis of AIMS Global Judgment Components (Items 8-10) in patients with TD from the ARM-TD and AIM-TD studies will be presented at the 32nd annual Psych Congress, October 3-6, 2019 in San Diego, California.
    • 31 Aug 2017 According to a Teva Pharmaceutical Industries media release, based on the results from AIM-TD and ARM-TD studies, the U.S. Food and Drug Administration (FDA) has approved AUSTEDO (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults.
    • 29 Jun 2017 According to a Teva Pharmaceutical, Karen E. Anderson and Hubert Fernandez were Principal Investigators of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top